Critères d'inclusion : - Gastroenteropancreatic neuroendocrine tumor (GEPNET), histologically proven, grade 1 or 2,
- Subject eligible for antitumor treatment initiation with lanreotide autogel*, alone or combined with other therapies, selected freely and prior to inclusion in the study by the physician,
- Subject able to complete a self-administered evaluation questionnaire during initiation visit and liable to be seen again within 6 months of the initial visit based on the physician's usual practices
- Having consented in writing to his/her data being accessed for participation in the study.
Critères de non-inclusion : - Previously treated by lanreotide autogel
- Simultaneously participating in a clinical trial